Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.66 USD
Change Today -0.21 / -5.43%
Volume 5.8K
OPGN On Other Exchanges
As of 8:10 PM 06/29/15 All times are local (Market data is delayed by at least 15 minutes).

opgen inc (OPGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/6/15 - $5.44
52 Week Low
05/21/15 - $3.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OPGEN INC (OPGN)

Related News

No related news articles were found.

opgen inc (OPGN) Related Businessweek News

No Related Businessweek News Found

opgen inc (OPGN) Details

OpGen, Inc. operates as an early commercial stage company using molecular testing and bioinformatics to assist healthcare providers to combat multi-drug-resistant bacterial infections. It offers Acuitas multi-drug-resistant organisms (MDRO) gene test, a molecular screening tool that detects 10 critical MDRO genes from 1 patient swab. The company also provides Acuitas CR Elite Test, which adds the ability to procure a standard microbiological culture result that provides additional information about the identified MDRO gene and its antibiotic susceptibility profile. In addition, it develops Acuitas Lighthouse MDRO bioinformatics product, which focuses on providing MDRO molecular information about an individual patient's resistance profile. OpGen, Inc. has a strategic collaboration with Hitachi High-Technologies Corporation to commercialize its genome mapping technology for mapping, assembly, and analysis of human DNA. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

29 Employees
Last Reported Date: 05/5/15
Founded in 2001

opgen inc (OPGN) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $95.0K
Chief Information Officer
Total Annual Compensation: $237.3K
Compensation as of Fiscal Year 2014.

opgen inc (OPGN) Key Developments

OpGen, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

OpGen, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenue of $472,200 against $1,097,205 against a year ago. Operating loss was $2,530,642 against $1,192,036 a year ago. Net loss was $2,595,173 against $1,200,201 a year ago. Net loss available to common stockholders was $2,766,914 against $1,311,016 a year ago. Basic and diluted net loss per common share was $5.61 against $3.62 a year ago. The reduction in revenue reflects previously announced strategic shift, as discussed in IPO prospectus filed on May 4, 2015, from Argus product sales and collaborative sales agreements, to providing rapid molecular testing and bioinformatics to combat multi-drug resistant organisms (MDROs).

OpGen, Inc. to Report Q1, 2015 Results on Jun 17, 2015

OpGen, Inc. announced that they will report Q1, 2015 results After-Market on Jun 17, 2015

OpGen, Inc., Q1 2015 Earnings Call, Jun 17, 2015

OpGen, Inc., Q1 2015 Earnings Call, Jun 17, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OPGN:US $3.66 USD -0.21

OPGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OPGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation OPGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OPGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at